Neurobiology of autism gene products: Towards pathogenesis and drug targets

Psychopharmacology

Volumn 231, Issue 6, 2014, Pages 1037-1062

  Kleijer, Kristel T E ^a   Schmeisser, Michael J ^b   Krueger, Dilja D ^c   Boeckers, Tobias M ^b   Scheiffele, Peter ^d   Bourgeron, Thomas ^e   Brose, Nils ^c   Burbach, J Peter H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ULM   (Germany)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

^e INSTITUT PASTEUR   (France)

Author keywords

Autism drug targets; Autism genetics; Autism spectrum disorders; CNTNAP2; Dendritic protein synthesis; Fragile X syndrome mouse models; Neurexin; Neuroligin; PTEN; SHANK

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; CONTACTIN; CONTACTIN ASSOCIATED PROTEIN LIKE 2; CTEP; EVEROLIMUS; FENOBAM; METABOTROPIC RECEPTOR ANTAGONIST; MEVINOLIN; NEUREXIN; NEUROLIGIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; RISPERIDONE; SALIRASIB; SCAFFOLD PROTEIN; SHANK1 PROTEIN; SHANK2 PROTEIN; SHANK3 PROTEIN; TEMSIROLIMUS; UNCLASSIFIED DRUG;

AHI1 GENE; AUTISM; CBP GENE; CDH10 GENE; CDH9 GENE; CNTN3 GENE; CNTN4 GENE; CNTN5 GENE; CNTN6 GENE; CNTNAP2 GENE; COMPULSION; CREBBP GENE; CYFIP1 GENE; DIAPH3 GENE; DISC1 GENE; DLG4 GENE; DRUG TARGETING; EIF4E GENE; EP300 GENE; FMR1 GENE; GENE PRODUCT; GRIN2A GENE; HUMAN; MBD5 GENE; MECP2 GENE; MEF2C GENE; MET GENE; NEUROBIOLOGY; NF1 GENE; NGLN4X GENE; NLGN3 GENE; NONHUMAN; NRCAM GENE; NRX1 GENE; PATHOGENESIS; PCDH10 GENE; PCDH9 GENE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; PSD95 GENE; PTEN GENE; REVIEW; SCN1A GENE; SHANK2 GENE; SHANK3 GENE; SIGNAL TRANSDUCTION; SSTR5 GENE; SYNAPTIC TRANSMISSION; SYNCAM1 GENE; TOP3B GENE; TSC1 GENE; TSC2 GENE; UBE3A GENE; VIPR GENE;

ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; PROTEINS; SIGNAL TRANSDUCTION;

EID: 84896718770     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3403-3     Document Type: Review

References (209)

1. Abrahams BS, Geschwind DH (2010) Connecting genes to brain in the autism spectrum disorders. Arch Neurol 67:395-399. doi:10.1001/archneurol.2010.47
2. Abrahams BS, Stone JL, Duvall JA et al (2008) Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 82:150-159. doi:10.1016/j.ajhg.2007.09.005 (Pubitemid 351726082)
3. Ackman JB, Aniksztejn L, Crépel V et al (2009) Abnormal network activity in a targeted genetic model of human double cortex. J Neurosci 29:313-327. doi:10.1523/JNEUROSCI.4093-08.2009
4. Alvarez Retuerto AI, Cantor RM, Gleeson JG et al (2008) Association of common variants in the Joubert syndrome gene (AHI1) with autism. Hum Mol Genet 17:3887-3896. doi:10.1093/hmg/ddn291 (Pubitemid 352762851)
5. Anderson GR, Gal T, Xu W, et al (2012) Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development. doi:10.1073/pnas.1216398109/-/DCSupplemental www.pnas.org/cgi/doi/10.1073/pnas.1216398109
6. Antar LN, Afroz R, Dictenberg JB et al (2004) Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci 24:2648-2655. doi:10.1523/JNEUROSCI.0099-04.2004 (Pubitemid 38380941)
7. Argyropoulos A, Gilby KL, Hill-Yardin EL (2013) Studying autism in rodent models: reconciling endophenotypes with comorbidities. Front Hum Neurosci 7:417. doi:10.3389/fnhum.2013.00417
8. Arons MH, Thynne CJ, Grabrucker AM et al (2012) Autism-associated mutations in ProSAP2/Shank3 impair synaptic transmission and neurexin-neuroligin-mediated transsynaptic signaling. J Neurosci 32:14966-14978. doi:10.1523/JNEUROSCI.2215-12.2012
9. Ascano M, Mukherjee N, Bandaru P et al (2012) FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature. doi:10.1038/ nature11737
10. Auerbach BD, Osterweil EK, Bear MF (2011) Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480:63-68. doi:10.1038/nature10658
11. Backman SA, Stambolic V, Suzuki A et al (2001) Deletion of PTEN in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 29:396-403. doi:10.1038/ng782 (Pubitemid 34326689)
12. Baron MK, Boeckers TM, Vaida B et al (2006) An architectural framework that may lie at the core of the postsynaptic density. Science 311:531-535. doi:10.1126/science.1118995
13. Baudouin SJ, Gaudias J, Gerharz S et al (2012) Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science 338:128-132. doi:10.1126/science.1224159
14. Bear MF, Huber KM, Warren ST (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377. doi:10.1016/j.tins.2004.04.009 (Pubitemid 38829251)
15. Bear MF, Dölen G, Osterweil E, Nagarajan N (2008) Fragile X: translation in action. Neuropsychopharmacology 33:84-87. doi:10.1038/sj.npp. 1301610 (Pubitemid 350191335)
16. Ben-Ari Y, Spitzer NC (2010) Phenotypic checkpoints regulate neuronal development. Trends Neurosci 33:485-492. doi:10.1016/j.tins.2010.08.005
17. Ben-Ari Y, Khalilov I, Kahle KT, Cherubini E (2012a) The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. Neuroscientist 18:467-486. doi:10.1177/1073858412438697
18. Ben-Ari Y, Woodin MA, Sernagor E et al (2012b) Refuting the challenges of the developmental shift of polarity of GABA actions: GABA more exciting than ever! Front Cell Neurosci 6:35. doi:10.3389/fncel.2012.00035
19. Berkel S, Marshall CR, Weiss B et al (2010) Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 42:489-491. doi:10.1038/ng.589
20. Berkel S, Tang W, Treviño M et al (2012) Inherited and de novo SHANK2 variants associated with autism spectrum disorder impair neuronal morphogenesis and physiology. Hum Mol Genet 21:344-357. doi:10.1093/hmg/ddr470
21. Berry-Kravis E, Hessl D, Coffey S et al (2009) A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46:266-271. doi:10.1136/jmg.2008.063701
22. Betancur C (2011) Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 1380:42-77. doi:10.1016/j.brainres.2010.11.078
23. Betancur C, Sakurai T, Buxbaum JD (2009) The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci 32:402-412. doi:10.1016/j.tins.2009.04.003
24. Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC et al (2012) Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76:325-337. doi:10.1016/j.neuron.2012.07.022
25. Bill BR, Geschwind DH (2009) Genetic advances in autism: heterogeneity and convergence on shared pathways. Curr Opin Genet Dev 19:271-278. doi:10.1016/j.gde.2009.04.004
26. Blankman JL, Cravatt BF (2013) Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65:849-871. doi:10.1124/pr.112.006387
27. Blumenthal GM, Dennis PA (2008) PTEN hamartoma tumor syndromes. Eur J Hum Genet 16:1289-1300. doi:10.1038/ejhg.2008.162
28. Blundell J, Blaiss CA, Etherton MR et al (2010) Neuroligin-1 deletion results in impaired spatialmemory and increased repetitive behavior. J Neurosci 30:2115-2129. doi:10.1523/JNEUROSCI.4517-09.2010
29. Boccuto L, Lauri M, Sarasua SM, et al (2012) Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet 1-7. doi:10.1038/ejhg.2012.175
30. Boeckers TM, Kreutz MR, Winter C et al (1999) Proline-rich synapseassociated protein-1/cortactin binding protein 1 (ProSAP1/CortBP1) is a PDZ-domain protein highly enriched in the postsynaptic density. J Neurosci 19:6506-6518 (Pubitemid 29347450)
31. Boeckers TM, Bockmann J, Kreutz MR, Gundelfinger ED (2002) ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem 81:903-910 (Pubitemid 34809273)
32. Borck G, Shin B-S, Stiller B et al (2012) eIF2aγ Mutation that disrupts eIF2 complex integrity links intellectual disability to impaired translation initiation. Mol Cell 48:641-646. doi:10.1016/j.molcel.2012.09.005
33. Bozdagi O, Sakurai T, Papapetrou D et al (2010) Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 1:15. doi:10.1186/2040-2392-1- 15
34. Bozdagi O, Tavassoli T, Buxbaum JD (2013) Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism 4:9. doi:10.1186/2040-2392-4-9
35. Budreck EC, Scheiffele P (2007) Neuroligin-3 is a neuronal adhesion protein at GABAergic and glutamatergic synapses. Eur J Neurosci 26:1738-1748. doi:10.1111/j.1460-9568.2007.05842.x (Pubitemid 47493212)
36. Busquets-Garcia A, Gomis-González M, Guegan T et al (2013) Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med 19:603-607. doi:10.1038/nm.3127
37. Butler MG, Dasouki MJ, Zhou X-P et al (2005) Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. JMed Genet 42:318-321. doi:10.1136/jmg.2004. 024646 (Pubitemid 40523954)
38. Buxbaum JD, Cai G, Chaste P et al (2007) Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet 144B:484-491. doi:10.1002/ajmg.b.30493 (Pubitemid 46983159)
39. Buxbaum JD, Daly MJ, Devlin B et al (2012) The Autism Sequencing Consortium: large-scale, high-throughput sequencing in autism spectrum disorders. Neuron 76:1052-1056. doi:10.1016/j.neuron.2012.12.008
40. Caglayan AO (2010) Genetic causes of syndromic and non-syndromic autism. Dev Med Child Neurol 52:130-138. doi:10.1111/j.1469-8749.2009.03523.x
41. Camacho-Garcia RJ, Planelles MI, Margalef M et al (2012) Mutations affecting synaptic levels of neurexin-1β in autism and mental retardation. Neurobiol Dis 47:135-143. doi:10.1016/j.nbd.2012.03.031
42. Campbell DB, Li C, Sutcliffe JS et al (2008) Genetic evidence implicating multiple genes in the METreceptor tyrosine kinase pathway in autism spectrum disorder. Autism Res 1:159-168. doi:10.1002/aur.27
43. Chadman KK, Gong S, Scattoni ML et al (2008) Minimal aberrant behavioral phenotypes of neuroligin-3 R451C knockin mice. Autism Res 1:147-158. doi:10.1002/aur.22
44. Chahrour M, Zoghbi HY (2007) The story of Rett syndrome: from clinic to neurobiology. Neuron 56:422-437. doi:10.1016/j.neuron.2007.10.001 (Pubitemid 350026269)
45. Chaste P, Leboyer M (2012) Autismrisk factors: genes, environment, and gene-environment interactions. Dialogues Clin Nuerosci 14:281-292
46. Chih B, Afridi SK, Clark L, Scheiffele P (2004) Disorder-associated mutations lead to functional inactivation of neuroligins. Hum Mol Genet 13:1471-1477. doi:10.1093/hmg/ddh158 (Pubitemid 39023055)
47. Chih B, Engelman H, Scheiffele P (2005) Control of excitatory and inhibitory synapse formation by neuroligins. Science 307(80-):1324-1328. doi:10.1126/science.1107470
48. Chilian B, Abdollahpour H, Bierhals T et al (2013) Dysfunction of SHANK2 and CHRNA7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci. Clin Genet. doi:10.1111/cge.12105
49. Ching MS, Shen Y, Tan WH et al (2010) Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am J Med Genet B Neuropsychiatr Genet 153B:937-947. doi:10.1002/ajmg.b.31063
50. Chubykin AA, Liu X, Comoletti D et al (2005) Dissection of synapse induction by neuroligins: effect of a neuroligin mutation associated with autism. J Biol Chem 280:22365-22374. doi:10.1074/jbc.M410723200 (Pubitemid 40834299)
51. Comoletti D, De Jaco A, Jennings LL et al (2004) The Arg451Cys- neuroligin-3 mutation associated with autism reveals a defect in protein processing. J Neurosci 24:4889-4893. doi:10.1523/JNEUROSCI.0468-04.2004 (Pubitemid 38668214)
52. Cooper GM, Coe BP, Girirajan S et al (2011) A copy number variation morbidity map of developmental delay. Nat Genet 43:838-846. doi:10.1038/ng.909
53. Crawley JN (2012) Translational animal models of autism and neurodevelopmental disorders. Dialogues Clin Neurosci 14:293-305
54. Daoud H, Bonnet-Brilhault F, Vedrine S et al (2009) Autism and non-syndromic mental retardation associated with a de novo mutation in the NLGN4X gene promoter causing an increased expression level. Biol Psychiatry 66:906-910. doi:10.1016/j.biopsych.2009.05.008
55. Darnell JC, Van Driesche SJ, Zhang C et al (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247-261. doi:10.1016/j.cell.2011.06.013
56. Delorme R, Ey E, Toro R et al (2013) Progress toward treatments for synaptic defects in autism. Nat Med 19:685-694. doi:10.1038/nm.3193
57. Denayer A, Van Esch H, de Ravel T, et al (2012) Neuropsychopathology in 7 patients with the 22q13 deletion syndrome: presence of bipolar disorder and progressive loss of skills. Mol Syndromol 14-20. doi:10.1159/000339119
58. Devlin B, Scherer SW (2012) Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev 22:229-237. doi:10.1016/j.gde.2012.03.002
59. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) PTEN is essential for embryonic development and tumour suppression. Nat Genet 19:348-355. doi:10.1038/1235 (Pubitemid 28357906)
60. Diaz-Ruiz O, Zapata A, Shan L et al (2009) Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons. PLoS One 4:e7027. doi:10.1371/journal.pone.0007027
61. Dölen G, Osterweil E, Rao BSS et al (2007) Correction of fragile X syndrome in mice. Neuron 56:955-962. doi:10.1016/j.neuron.2007.12.001 (Pubitemid 350251119)
62. Domanskyi A, Geissler C, Vinnikov IA et al (2011) PTEN ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J 25:2898-2910. doi:10.1096/fj.11-181958
63. Du Y, Weed SA, Xiong Wet al (1998) Identification of a novel cortactin SH3 domain-binding protein and its localization to growth cones of cultured neurons identification of a novel cortactin SH3 domain-binding protein and its localization to growth cones of cultured neurons. Mol Cell Biol 18:5838-5851 (Pubitemid 28450535)
64. Dudanova I, Tabuchi K, Rohlmann A, Missler M (2007) Deletion of neurexins does not cause a major impairment of axonal pathfinding or synapse formation. 274:261-274. doi:10.1002/cne
65. DurandCM, Betancur C, Boeckers TMet al (2007)Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 39:25-27. doi:10.1038/ng1933 (Pubitemid 46026497)
66. Durand CM, Perroy J, Loll F et al (2012) SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 17:71-84. doi:10.1038/mp.2011.57
67. Ebert DH, Greenberg ME (2013) Activity-dependent neuronal signalling and autism spectrum disorder. Nature 493:327-337. doi:10.1038/nature11860
68. Edge L (2012) mTOR: the master regulator. Cell 149:955-957. doi:10.1016/j.cell.2012.05.011
69. Ehninger D (2013) From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology 68:97-105. doi:10.1016/j.neuropharm.2012.05.015
70. Ehninger D, Silva AJ (2011) Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol Med 17:78-87. doi:10.1016/j.molmed.2010. 10.002
71. Ehninger D, Han S, Shilyansky C et al (2008a) Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 14:843-848. doi:10.1038/nm1788
72. Ehninger D, Li W, Fox K et al (2008b) Reversing neurodevelopmental disorders in adults. Neuron 60:950-960
73. Ehninger D, de Vries PJ, Silva AJ (2009) From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res 53:838-851. doi:10.1111/j.1365-2788.2009. 01208.x
74. El-Kordi A, Winkler D, Hammerschmidt K et al (2012) Development of an autism severity score for mice using Nlgn4 null mutants as a construct-valid model of heritable monogenic autism. Behav Brain Res. doi:10.1016/j.bbr.2012.11. 016
75. Endersby R, Baker SJ (2008) PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27:5416-5430. doi:10.1038/onc.2008.239
76. Erickson CA, Early M, Stigler KA et al (2011) An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol 21:565-569. doi:10.1089/cap.2011.0034
77. Erickson CA, Wink LK, Ray B et al (2013) Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 228:75-84. doi:10.1007/s00213-013-3022-z
78. Etherton MR, Blaiss CA, Powell CM, Sudhof TC (2009) Mouse neurexin- 1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc Natl Acad Sci U S A 106:17998-18003. doi:10.1073/pnas.0910297106
79. Etherton M, Foldy C, Sharma M et al (2011) Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proc Natl Acad Sci U S A 108:13764-13769. doi:10.1073/pnas.1111093108
80. Ey E, Yang M, Katz a M, et al (2012) Absence of deficits in social behaviors and ultrasonic vocalizations in later generations of mice lacking neuroligin4. Genes Brain Behav 928-941. doi:10.1111/j.1601-183X.2012.00849.x
81. Feng J, Schroer R, Yan J et al (2006) High frequency of neurexin 1beta signal peptide structural variants in patients with autism. Neurosci Lett 409:10-13. doi:10.1016/j.neulet.2006.08.017 (Pubitemid 44585112)
82. Fernandez TV, García-González IJ, Mason CE et al (2008) Molecular characterization of a patient with 3p deletion syndrome and a review of the literature. Am J Med Genet A 146A:2746-2752. doi:10.1002/ajmg.a.32533
83. Földy C,Malenka RC, Südhof TC (2013) Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron 78:498-509. doi:10.1016/j.neuron.2013.02.036
84. Fraser MM, Zhu X, Kwon C-H et al (2004) PTEN loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 64:7773-7779. doi:10.1158/0008-5472.CAN-04-2487 (Pubitemid 39446909)
85. Fraser MM, Bayazitov IT, Zakharenko SS, Baker SJ (2008) Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience 151:476-488. doi:10.1016/j.neuroscience.2007.10.048
86. Gargus JJ (2006) Ion channel functional candidate genes in multigenic neuropsychiatric disease. Biol Psychiatry 60:177-185. doi:10.1016/j.biopsych. 2005.12.008
87. Gauthier J, Spiegelman D, Piton A et al (2009) Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 150B:421-424. doi:10.1002/ajmg.b.30822
88. Gauthier J, Champagne N, Lafrenière RG et al (2010) De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A 107:7863-7868. doi:10.1073/pnas.0906232107
89. Gilman SR, Iossifov I, Levy D et al (2011) Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 70:898-907. doi:10.1016/j.neuron. 2011.05.021
90. Gkogkas CG, Khoutorsky A, Ran I et al (2012) Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature. doi:10.1038/ nature11628
91. Grabrucker AM (2012) Environmental factors in autism. Front Psychiatry 3:118. doi:10.3389/fpsyt.2012.00118
92. Grabrucker AM, Knight MJ, Proepper C et al (2011a) Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation. EMBO J 30:569-581. doi:10.1038/emboj.2010.336
93. Grabrucker AM, Schmeisser MJ, Schoen M, Boeckers TM (2011b) Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. Trends Cell Biol 21:594-603. doi:10.1016/j.tcb.2011.07.003
94. Grayton HM, Missler M, Collier DA, Fernandes C (2013) Altered social behaviours in neurexin 1α knockout mice resemble core symptoms in neurodevelopmental disorders. PLoS One 8:e67114. doi:10.1371/journal.pone. 0067114
95. Groszer M, Erickson R, Scripture-Adams DD et al (2001) Negative regulation of neural stem/progenitor cell proliferation by the PTEN tumor suppressor gene in vivo. Science 294:2186-2189. doi:10.1126/science.1065518 (Pubitemid 33150679)
96. Gutierrez RC, Hung J, Zhang Y et al (2009) Altered synchrony and connectivity in neuronal networks expressing an autism-related mutation of neuroligin 3. Neuroscience 162:208-221. doi:10.1016/j.neuroscience.2009.04.062
97. Guy J, Gan J, Selfridge J et al (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143-1147. doi:10.1126/science. 1138389 (Pubitemid 46328028)
98. Hamdan FF, Gauthier J, Araki Y et al (2011) Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 88:306-316. doi:10.1016/j.ajhg.2011.02. 001
99. Hanssen AMN (1995) Syndrome of the month Cowden syndrome. 117-119
100. Herman GE, Butter E, Enrile B, et al (2007) Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. 593:589-593. doi: 10.1002/ajmg.a
101. Hobert JA, Eng C (2009) PTEN hamartoma tumor syndrome: an overview. Genet Med 11:687-694. doi:10.1097/GIM.0b013e3181ac9aea
102. Hoon M, Soykan T, Falkenburger B et al (2011) Neuroligin-4 is localized to glycinergic postsynapses and regulates inhibition in the retina. Proc Natl Acad Sci U S A 108:3053-3058. doi:10.1073/pnas.1006946108
103. Horresh I, Poliak S, Grant S et al (2008) Multiple molecular interactions determine the clustering of Caspr2 and Kv1 channels in myelinated axons. J Neurosci 28:14213-14222. doi:10.1523/JNEUROSCI.3398-08.2008
104. Hung AY, Futai K, Sala C et al (2008) Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci 28:1697-1708. doi:10.1523/JNEUROSCI.3032-07.2008 (Pubitemid 351287038)
105. Jacquemont S, Curie A, des Portes V, et al (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3:64ra1. doi:10.1126/ scitranslmed.3001708
106. Jaeken J, Matthijs G (2007) Congenital disorders of glycosylation: a rapidly expanding disease family. Annu Rev Genomics Hum Genet 8:261-278. doi:10.1146/annurev.genom.8.080706.092327
107. Jamain S, Quach H, Betancur C et al (2003) Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34:27-29. doi:10.1038/ng1136 (Pubitemid 36548785)
108. Jamain S, Radyushkin K, Hammerschmidt K et al (2008) Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc Natl Acad Sci U S A 105:1710-1715. doi:10.1073/pnas.0711555105 (Pubitemid 351346579)
109. Jiang Y-H, Ehlers MD (2013) Modeling autism by SHANK gene mutations in mice. Neuron 78:8-27. doi:10.1016/j.neuron.2013.03.016
110. Kano M, Ohno-shosaku T, Hashimotodani Y, Uchigashima M (2009) Endocannabinoid-mediated control of synaptic transmission. 309-380. doi:10.1152/physrev.00019.2008
111. Kas MJ, Glennon JC, Buitelaar J et al (2013) Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives. Psychopharmacology (Berl). doi:10.1007/s00213-013-3268-5
112. Kelleher RJ, Bear MF (2008) The autistic neuron: troubled translation? Cell 135:401-406. doi:10.1016/j.cell.2008.10.017
113. King IF, Yandava CN, Mabb AM et al (2013) Topoisomerases facilitate transcription of long genes linked to autism. Nature 501:58-62. doi:10.1038/nature12504
114. Kirov G, Gumus D, Chen W et al (2008) Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 17:458-465. doi:10.1093/hmg/ddm323
115. Krey JF, Paşca SP, Shcheglovitov A et al (2013) Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. Nat Neurosci 16:201-209. doi:10.1038/nn.3307
116. Krueger DD, Tuffy LP, Papadopoulos T, Brose N (2012) The role of neurexins and neuroligins in the formation, maturation, and function of vertebrate synapses. Curr Opin Neurobiol 22:412-422. doi:10.1016/j.conb.2012.02. 012
117. Kumamoto N, Gu Y, Wang J et al (2012) A role for primary cilia in glutamatergic synaptic integration of adult-born neurons. Nat Neurosci 15(399-405):S1. doi:10.1038/nn.3042
118. Kwon CH, Zhu X, Zhang J et al (2001) PTEN regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 29:404-411. doi:10.1038/ng781 (Pubitemid 34326690)
119. Kwon C-H, Zhu X, Zhang J, Baker SJ (2003) mTor is required for hypertrophy of PTEN-deficient neuronal soma in vivo. Proc Natl Acad Sci U S A 100:12923-12928. doi:10.1073/pnas.2132711100 (Pubitemid 37340001)
120. Kwon C-H, Luikart BW, Powell CM et al (2006) PTEN regulates neuronal arborization and social interaction in mice. Neuron 50:377-388. doi:10.1016/j.neuron.2006.03.023
121. Kwon HB, Kozorovitskiy Y, OhWJ et al (2012) Neuroligin-1-dependent competition regulates cortical synaptogenesis and synapse number. Nat Neurosci 15:1667-1674. doi:10.1038/nn.3256
122. Lamolet B, Pulichino AM, Lamonerie T et al (2001) A pituitary cellrestricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104:849-859 (Pubitemid 32289278)
123. Leblond CS, Heinrich J, Delorme R et al (2012) Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet 8:e1002521. doi:10.1371/journal.pgen.1002521
124. Lee JE, Gleeson JG (2011) Cilia in the nervous system: linking cilia function and neurodevelopmental disorders. Curr Opin Neurol 24:98-105. doi:10.1097/WCO.0b013e3283444d05
125. Lemonnier E, Ben-Ari Y (2010) The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr 99:1885-1888. doi:10.1111/j.1651-2227.2010.01933.x
126. Lemonnier E, Degrez C, Phelep M et al (2012) A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2:e202. doi:10.1038/tp.2012.124
127. Lesche R, Groszer M, Gao J, et al (2002) Cre/loxP-mediated inactivation of the murine PTEN tumor suppressor gene. 149:148-149. doi:10.1002/gene.10036
128. Leslie NR, Downes CP (2004) PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382:1-11 (Pubitemid 39141560)
129. Levinson JN, Li R, Kang R et al (2010) Postsynaptic scaffolding molecules modulate the localization of neuroligins. Neuroscience 165:782-793. doi:10.1016/j.neuroscience.2009.11.016
130. Li J (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(80-):1943-1947. doi:10.1126/science.275.5308.1943
131. Lintas C, Persico AM (2009) Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. J Med Genet 46:1-8. doi:10.1136/jmg.2008.060871
132. Maehama T, Dixon JE (1999) PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 9:125-128 (Pubitemid 29161437)
133. Maehama T, Taylor GS, Dixon JE (2001) PTEN and Myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 70:247-279 (Pubitemid 32662211)
134. Marino S, Krimpenfort P, Leung C et al (2002) PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 129:3513-3522
135. McBride KL, Varga EA, Pastore MT et al (2010) Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res 3:137-141. doi:10.1002/aur.132
136. Michalon A, Sidorov M, Ballard TM et al (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74:49-56. doi:10.1016/j.neuron.2012.03.009
137. Millan MJ (2013) An epigenetic framework for neurodevelopmental disorders: from pathogenesi s to potent ial therapy. Neuropharmacology 68:2-82. doi:10.1016/j.neuropharm.2012.11.015
138. Moessner R, Marshall CR, Sutcliffe JS et al (2007) Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 81:1289-1297. doi:10.1086/522590 (Pubitemid 350211458)
139. Murphy D, SpoorenW(2012) EU-AIMS: a boost to autism research. Nat Rev Drug Discov 11:815-816. doi:10.1038/nrd3881
140. Naisbitt S, Kim E, Tu JC, et al (1999) Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and Cortactin University of North Carolina at Chapel Hill. 23:569-582
141. Napoli I, Mercaldo V, Boyl PP et al (2008) The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134:1042-1054. doi:10.1016/j.cell.2008.07.031
142. Napoli E, Ross-Inta C,Wong S et al (2012)Mitochondrial dysfunction in PTEN haplo-insufficient mice with social deficits and repetitive behavior: interplay between PTEN and p53. PLoS One 7:e42504. doi:10.1371/journal.pone. 0042504
143. Neves-Pereira M, Müller B, Massie D et al (2009) Deregulation of EIF4E: a novel mechanism for autism. J Med Genet 46:759-765. doi:10.1136/jmg.2009.066852
144. Novarino G, Akizu N, Gleeson JG (2011) Modeling human disease in humans: the ciliopathies. Cell 147:70-79. doi:10.1016/j.cell.2011.09.014
145. O'Roak BJ, Deriziotis P, Lee C et al (2011) Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 43:585-589. doi:10.1038/ng.835
146. Olexová L, Talarovičová A, Lewis-Evans B et al (2012) Animal models of autism with a particular focus on the neural basis of changes in social behaviour: an update article. Neurosci Res 74:184-194. doi:10.1016/j.neures.2012.10.004
147. Orloff MS, Eng C (2008) Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.Oncogene 27:5387-5397. doi:10.1038/onc.2008.237
148. Osterweil EK, Krueger DD, Reinhold K, Bear MF (2010) Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 30:15616-15627. doi:10.1523/JNEUROSCI.3888-10.2010
149. Osterweil EK, Chuang S-C, Chubykin AA et al (2013) Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77:243-250. doi:10.1016/j.neuron.2012.01.034
150. Peça J, Feliciano C, Ting JT et al (2011) Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472:437-442. doi:10.1038/nature09965
151. Peñagarikano O, Geschwind DH (2012) What does CNTNAP2 reveal about autism spectrum disorder? TrendsMolMed 18:156-163. doi:10.1016/j.molmed.2012.01. 003
152. Peñagarikano O, Abrahams BS, Herman EI et al (2011) Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 147:235-246. doi:10.1016/j.cell.2011.08.040
153. Phelan K, McDermid HE (2011) The 22q13.3 deletion syndrome (Phelan-McDermid Syndrome). Mol Syndromol. 186-201. doi:10.1159/000334260
154. Pinto D, Pagnamenta AT, Klei L et al (2010) Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466:368-372. doi:10.1038/nature09146
155. Poliak S, Peles E (2003) The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 4:968-980. doi:10.1038/nrn1253 (Pubitemid 37486673)
156. Poliak S, Gollan L,Martinez R et al (1999) Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+channels. Neuron 24:1037-1047 (Pubitemid 30017681)
157. Pop AS, Levenga J, de Esch CEF et al (2012) Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology (Berl). doi:10.1007/s00213-012-2947-y
158. Poulopoulos A, Soykan T, Tuffy LP et al (2012) Homodimerization and isoform-specific heterodimerization of neuroligins. Biochem J 446:321-330. doi:10.1042/BJ20120808
159. Radyushkin K, Hammerschmidt K, Boretius S et al (2009) Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav 8:416-425. doi:10.1111/j.1601-183X.2009. 00487.x
160. Reichelt AC, Rodgers RJ, Clapcote SJ (2012) The role of neurexins in schizophrenia and autistic spectrum disorder. Neuropharmacology 62:1519-1526. doi:10.1016/j.neuropharm.2011.01.024
161. Rujescu D, Ingason A, Cichon S et al (2009) Disruption of the neurexin 1 gene is associated with schizophrenia. HumMol Genet 18:988-996. doi:10.1093/hmg/ddn351
162. Sahin M (2012) Targeted treatment trials for tuberous sclerosis and autism: no longer a dream. Curr Opin Neurobiol 22:895-901. doi:10.1016/j.conb. 2012.04.008
163. Sanders SJ, Ercan-Sencicek AG, Hus V et al (2011)Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70:863-885. doi:10.1016/j.neuron.2011. 05.002
164. Sanders SJ, Murtha MT, Gupta AR et al (2012) De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485:237-241. doi:10.1038/nature10945
165. Santini E, Huynh TN,MacAskill AF et al (2013) Exaggerated translation causes synaptic and behavioral aberrations associated with autism. Nature 493:411-415. doi:10.1038/nature11782.Exaggerated
166. Sato D, Lionel AC, Leblond CS et al (2012) SHANK1 deletions in males with autism spectrum disorder. Am J Hum Genet 90:879-887. doi:10.1016/j.ajhg.2012. 03.017
167. Schaaf CP, Boone PM, Sampath S et al (2012) Phenotypic spectrum and genotype-phenotype correlations of NRXN1 exon deletions. Eur J Hum Genet 20:1240-1247. doi:10.1038/ejhg.2012.95
168. Schmeisser MJ, Ey E, Wegener S et al (2012) Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature 486:256-260. doi:10.1038/nature11015
169. Shcheglovitov A, Shcheglovitova O, Yazawa M et al (2013) SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature. doi:10.1038/nature12618
170. Sheng M, Kim E (2000) The Shank family of scaffold proteins. J Cell Sci 113(Pt 1):1851-1856 (Pubitemid 30386489)
171. Shinoda Y, Sadakata T, Furuichi T (2013) Animal models of autism spectrum disorder (ASD): a synaptic-level approach to autistic-like behavior in mice. Exp Anim 62:71-78
172. Silverman JL, Yang M, Lord C, Crawley JN (2010) Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci 11:490-502. doi:10.1038/nrn2851
173. Silverman JL, Turner SM, Barkan CL et al (2011) Sociability and motor functions in Shank1 mutant mice. Brain Res 1380:120-137. doi:10.1016/j.brainres. 2010.09.026
174. Soulard A, Hall MN (2007) SnapShot: mTOR signaling. Cell 129:434. doi:10.1016/j.cell.2007.04.010
175. Sperow M, Berry RB, Bayazitov IT et al (2012) Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration. J Physiol 590:777-792. doi:10.1113/jphysiol. 2011.220236
176. Spooren W, Lindemann L, Ghosh A, Santarelli L (2012) Synapse dysfunction in autism: amolecularmedicine approach to drug discovery in neurodevelopmental disorders. Trends Pharmacol Sci 1-16. doi:10.1016/j.tips.2012.09.004
177. State MW, Levitt P (2011) The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci 14:1499-1506. doi:10.1038/nn.2924
178. Steck PA, Pershouse MA, Jasser SA et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362 (Pubitemid 27147102)
179. Stoll G, Pietiläinen OPH, Linder B et al (2013) Deletion of TOP3β, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. Nat Neurosci 16:1228-1237. doi:10.1038/nn.3484
180. Sudhof TC (2008) Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455:903-911. doi:10.1038/nature07456
181. Sulis M (2003) PTEN: from pathology to biology. Trends Cell Biol 13:478-483. doi:10.1016/S0962-8924(03)00175-2
182. Suzuki A, de la Pompa JL, Stambolic V et al (1998) High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8:1169-1178 (Pubitemid 28494715)
183. Tabuchi K, Blundell J, Etherton MR et al (2007) A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science 318(80-):71-76. doi:10.1126/science.1146221
184. Takeuchi K, Gertner MJ, Zhou J, et al (2013) Dysregulation of synaptic plasticity precedes appearance of morphological defects in a PTEN conditional knockout mouse model of autism. doi:10.1073/pnas.1222803110/-/DCSupplemental www.pnas.org/cgi/doi/10.1073/pnas.1222803110
185. Tanaka H, Miyazaki N, Matoba K et al (2012) Higher-order architecture of cell adhesion mediated by polymorphic synaptic adhesion molecules neurexin and neuroligin. Cell Rep 2:101-110. doi:10.1016/j.celrep.2012.06.009
186. Ting JT, Peça J, Feng G (2012) Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annu Rev Neurosci 35:49-71. doi:10.1146/annurev-neuro-062111-150442
187. Tropea D, Giacometti E, Wilson NR et al (2009) Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A 106:2029-2034. doi:10.1073/pnas.0812394106
188. Van der Zwaag B, Franke L, Poot M et al (2009) Gene-network analysis identifies susceptibility genes related to glycobiology in autism. PLoS One 4:e5324. doi:10.1371/journal.pone.0005324
189. Van Diepen MT, Eickholt BJ (2008) Function of PTEN during the formation and maintenance of neuronal circuits in the brain. Dev Neurosci 30:59-64. doi:10.1159/000109852 (Pubitemid 350256684)
190. Van Spronsen M, Hoogenraad CC (2010) Synapse pathology in psychiatric and neurologic disease. Curr Neurol Neurosci Rep 10:207-214. doi:10.1007/s11910- 010-0104-8
191. Varga EA, Pastore M, Prior T et al (2009) The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med 11:111-117. doi:10.1097/GIM.0b013e31818fd762
192. Varoqueaux F, Aramuni G, Rawson RL et al (2006) Neuroligins determine synapse maturation and function. Neuron 51:741-754. doi:10.1016/j.neuron.2006. 09.003 (Pubitemid 44374915)
193. Verpelli C, Schmeisser MJ, Sala C, Boeckers TM (2012) Synaptic plasticity: scaffold proteins at the postsynaptic density. 970:29-62. doi:10.1007/978-3-7091-0932-8
194. Wang DO, Kim SM, Zhao Y et al (2009) Synapse- and stimulus-specific local translation during long-term neuronal plasticity. Science 324:1536-1540. doi:10.1126/science.1173205
195. Wang X, McCoy PA, Rodriguiz RM et al (2011) Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet 20:3093-3108. doi:10.1093/hmg/ddr212
196. Wöhr M, Roullet FI, Hung AY et al (2011) Communication impairments in mice lacking Shank1: reduced levels of ultrasonic vocalizations and scent marking behavior. PLoS One 6:e20631. doi:10.1371/journal.pone.0020631
197. Wöhr M, Silverman JL, Scattoni ML et al (2013) Developmental delays and reduced pup ultrasonic vocalizations but normal sociability in mice lacking the postsynaptic cell adhesion protein neuroligin2. Behav Brain Res 251:50-64. doi:10.1016/j.bbr.2012.07.024
198. Won H, Lee H-R, Gee HY et al (2012) Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486:261-265. doi:10.1038/nature11208
199. Won H, Mah W, Kim E (2013) Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses. Front Mol Neurosci 6:1-26. doi:10.3389/fnmol.2013.00019
200. Xu D, ShenW, Guo R et al (2013) Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. Nat Neurosci 16:1238-1247. doi:10.1038/nn.3479
201. Yan J, Oliveira G, Coutinho A et al (2005) Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. Mol Psychiatry 10:329-332. doi:10.1038/sj.mp.4001629
202. Yang M, Bozdagi O, Scattoni ML et al (2012) Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci 32:6525-6541. doi:10.1523/JNEUROSCI.6107-11.2012
203. Yue Q, Groszer M, Gil JS et al (2005) PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. Development 132:3281-3291. doi:10.1242/dev.01891 (Pubitemid 41167155)
204. Zhang C, Milunsky JM, Newton S et al (2009) A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export. J Neurosci 29:10843-10854. doi:10.1523/JNEUROSCI.1248-09.2009
205. Zhou J, Parada LF (2012) PTEN signaling in autism spectrum disorders. Curr Opin Neurobiol 22:873-879. doi:10.1016/j.conb.2012.05.004
206. Zhou J, Blundell J, Ogawa S et al (2009) Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific PTEN knock-out mice. J Neurosci 29:1773-1783. doi:10.1523/JNEUROSCI.5685-08.2009
207. Zhu G, Chow LML, Bayazitov IT et al (2012) PTEN deletion causes mTorc1-dependent ectopic neuroblast differentiation without causing uniform migration defects. Development 139:3422-3431. doi:10.1242/dev.083154
208. Zoghbi HY (2003) Postnatal neurodevelopmental disorders: meeting at the synapse? Science 302:826-830. doi:10.1126/science.1089071
209. Zoghbi HY, Bear MF (2012) Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol. doi:10.1101/cshperspect.a009886